Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Mohty, Mohamad  [Clear All Filters]
Journal Article
Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Remenyi PPal, Versluis J, Rovira M, Blaise D, et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT. Blood. 2024.
Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, et al. WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplant Cell Ther. 2022.
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet EMaria, Versluis J, Schroeder T, Blau IWolfgang, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.
Giebel S, Czyż A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin N-C, Savani B, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the acute leukemia working party of the . Cancer. 2016.
Hamed RAl, Ngoya M, Galimard J-E, Sengeloev H, Gedde-Dahl T, Kulagin A, Platzbecker U, Yakoub-Agha I, Byrne JL, Valerius T, et al. Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study. Cancer. 2023.
Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9(1):89.
Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2014.
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R-M, Niederwieser D, Volin L, Markiewicz M, Arnold R, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. An ALWP/EBMT analysis. J Intern Med. 2018.
Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JHenri, Socié G, Forcade E, Yakoub-Agha I, Labussière-Wallet H, Bethge W, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023.
Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M, Savani B, Spyridonidis A, Hamladji R-M, Potter V, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par. Bone Marrow Transplant. 2022.
Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JLuiz, Bruno B, Castagna L, Moiseev ISergeevich, Vitek A, et al. The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. Biol Blood Marrow Transplant. 2020.
Saraceni F, Labopin M, Raiola AM, Blaise D, Reményi P, Sorà F, Pavlu J, Bramanti S, Busca A, Berceanu A, et al. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7(10):e952.
Battipaglia G, Labopin M, Mielke S, Ruggeri A, Ozkurt ZNur, Bourhis JHenri, Rabitsch W, Yakoub-Agha I, Grillo G, Sanz J, et al. Thiotepa-based regimens are a valid alternative to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT. Transplant Cell Ther. 2023.
Gavriilaki E, Sakellari I, Labopin M, Bornhäuser M, Hamladji R-M, Casper J, Edinger M, Žák P, Yakoub-Agha I, Ciceri F, et al. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute . Bone Marrow Transplant. 2023.
Gorin N-C, Labopin M, Blaise D, de Groot M, Socié G, Bourhis JHenri, Ciceri F, Polge E, Nagler A, Mohty M. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood a. Cancer. 2019.
Belkacemi Y, Labopin M, Giebel S, Gorin NClaude, Loganadane G, Miszczyk L, Michallet M, Socié G, Schaap NPm, Cornelissen JJ, et al. Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. Int J Radiat Oncol Biol Phys. 2018.
Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, et al. Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of th. Hemasphere. 2023;7(7):e920.
Li Z, Mewawalla P, Stratton P, Yong ASM, Shaw BE, Hashmi S, Jagasia M, Mohty M, Majhail NS, Savani BN, et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer. 2015.
Le Bourgeois A, Labopin M, Marçais A, de Latour RPeffault, Blaise D, Chantepie S, N'Guyen S, Maillard N, Forcade E, Yakoub-Agha I, et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020.
Velázquez GFilippini, Labopin M, Tischer J, Raiola AMaria, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois C-E, Kröger N, et al. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.
Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019.
Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020.
de Latour RPeffault, Chevret S, Ruggeri ALisa, Suarez F, Souchet L, Michonneau D, de Fontbrune FSicre, Coman T, Dhedin N, Rubio MThérèse, et al. Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial. Blood. 2019.
Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke G-N, Blau IWolfgang, Salmenniemi U, Socié G, et al. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplant. 2023.

Pages